Genomics Alterations in Cancer
Course Information
PMTO 207 Genomics Alterations in Cancer
- 3 units
- Quarter Offered: Winter
- Instructors: Shumei Kato, M.D., Medical Oncologist, Associate Clinical Professor of Medicine, UC San Diego Moores Cancer Center; Sandip P Patel, M.D., Professor, Medical Oncology, UC San Diego Leader, Experimental Therapeutics/ Co-Leader, Solid Tumor Therapeutics, Deputy Director, Sanford Stem Cell Clinical Center, Medical Director, Clinical Research Informatics
Course Description & Learning Objectives
Along with rapid technological advancement, interrogating genomic alterations among individual cancer patients, such as with next-generation genomic sequencing, is now routinely done. As a result, many actionable molecular targets for cancer treatment emerged that potentially predict the response to both targeted and immunotherapies. Certain germline alterations that are associated with hereditary cancer predisposition syndromes are also rapidly recognized as an important factor for treatment selection.The course will also discuss the conundrum of genomic driver in benign conditions. Upon completion of this course, students will have a better understanding of cancer genomics and its actionability for matching patients with targeted therapy and immunotherapy.Learning Outcomes & Skills Acquired from the Course
After completion of this course, students will acquire the skills to be able to understand:- The cancer associated genomic alteration in general, as well as how to translate the information for targeted anti-cancer therapy approaches.
- Somatic Alterations in cancer
- Specific somatic mutations that are important for cancer care Oncogenic drivers and benign conditions.
- Hereditary Cancer Predisposition Syndromes
- Linking genomics and immune system biology